- Home
- OPFI vs FENC Comparison
OPFI vs FENC Comparison
Compare OPFI & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- FENC
- Stock Information
- Founded
- OPFI 2009
- FENC 1996
- Country
- OPFI United States
- FENC United States
- Employees
- OPFI N/A
- FENC N/A
- Industry
- OPFI Finance: Consumer Services
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPFI Finance
- FENC Health Care
- Exchange
- OPFI Nasdaq
- FENC Nasdaq
- Market Cap
- OPFI 174.4M
- FENC 156.9M
- IPO Year
- OPFI N/A
- FENC 2001
- Fundamental
- Price
- OPFI $12.64
- FENC $6.23
- Analyst Decision
- OPFI Buy
- FENC Strong Buy
- Analyst Count
- OPFI 2
- FENC 2
- Target Price
- OPFI $7.50
- FENC $14.00
- AVG Volume (30 Days)
- OPFI 1.9M
- FENC 64.0K
- Earning Date
- OPFI 03-06-2025
- FENC 03-20-2025
- Dividend Yield
- OPFI N/A
- FENC N/A
- EPS Growth
- OPFI 775.86
- FENC N/A
- EPS
- OPFI 0.38
- FENC N/A
- Revenue
- OPFI $260,661,000.00
- FENC $49,348,000.00
- Revenue This Year
- OPFI N/A
- FENC $170.43
- Revenue Next Year
- OPFI $6.51
- FENC $6.70
- P/E Ratio
- OPFI $33.44
- FENC N/A
- Revenue Growth
- OPFI 23.85
- FENC 278.09
- 52 Week Low
- OPFI $2.35
- FENC $3.96
- 52 Week High
- OPFI $12.84
- FENC $11.49
- Technical
- Relative Strength Index (RSI)
- OPFI 75.07
- FENC 59.87
- Support Level
- OPFI $11.45
- FENC $5.45
- Resistance Level
- OPFI $12.50
- FENC $6.19
- Average True Range (ATR)
- OPFI 1.04
- FENC 0.29
- MACD
- OPFI 0.31
- FENC -0.01
- Stochastic Oscillator
- OPFI 96.52
- FENC 85.71
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.